Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-23 · accession 0000875320-24-000099 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | 2024-02-26 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $425.70 | -5,034 | 49.7K | -9% | -$2.14M | |
| 2024-02-27 | 2024-02-23 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $431.79 | -4,714 | 54.7K | -8% | -$2.04M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-26 | S | D | 5,034 | $425.70 | 49,691 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-23 | F | D | 4,714 | $431.79 | 54,725 | D | — | — |